Visiopharm Becomes a Technology Leader in Deep Learning and AI Image Analysis for Digital Pathology

October 3rd, 2018

Visiopharm Launches AI Powered by Deep Learning: Letting Pathologists Harness the Power of AI

The Oncotopix®/Biotopix™ AI image analysis platform is powered by the latest technological breakthroughs in AI and Deep Learning, providing the most comprehensive solution for image analysis available for Digital Pathology today.

With near infinite configurability, the Visiopharm AI software platform addresses even the most complex and challenging image analysis applications. This allows scientists and researchers to grow and evolve with their research without constantly hitting the walls of software limitations.

Read more

Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis

September 10th, 2018

Visiopharm Phenomap software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research 

Fluidigm Corporation (NASDAQ:FLDM) and Visiopharm A/S today announced a co-marketing relationship to automate image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of this agreement, Fluidigm and Visiopharm will cooperatively promote Visiopharm® image analysis software in conjunction with the Fluidigm® Hyperion™ Imaging System, MCD™ Viewer software and related Maxpar® antibodies and kits.

Read more

LAUNCHING Phenomap™ - New Automated Phenotyping Software Tool Streamlined Analysis Workflow of High Dimensional Images

September 7th, 2018

Introducing Visiopharm Phenomap™ Multiplexing a novel software tool to help you streamline and automate the analysis workflow of high dimensional multiplex datasets, for deeper understanding of potential relationships in the tumor microenvironment (TME).

Phenomap™ offers a streamlined and intuitive workflow for simultaneous analysis of up to 255 channels by automatically identifying individual cells and performing cell-based phenotyping in high dimensional multiplex images.

Researchers and scientists have a growing necessity for simultaneous analysis of multiple biomarkers to identify immune cells within the tumor microenvironment (TME). Imaging the tumor microenvironment has inherent problems as there are many different types of immune cells to identify.

Read more

Strong consortium invests nearly DKK 100 million (€ 13.3 million) into Danish image analysis leader, Visiopharm A/S

August 24th, 2018

ATP, the Danish Growth Fund and the C. L. David Foundation and Collection are among the new investors. The increased capital commitment is an essential part of the company’s growth strategy within the field of tissue diagnostics- and research software for cancer.

Visiopharm A/S, is developing software for tissue based cancer diagnostics, based on image analysis that integrates precision- and high-throughput pathology in diagnostic workflows. ATP is investing DKK 45 million, the Danish Growth Fund is putting in DKK 20 million and the C. L. David Foundation is financing with DKK 15 million. In addition, the existing investor Northcap Venture Partners has invested a further DKK 15 million. The remaining investment is supplied by smaller shareholders/owners. In addition to the investors, the owners moving forward will thus be comprised of the founders, Michael Grunkin and Johan Doré Hansen, as well as a number of smaller shareholders. The investment is the basis for further international growth.

Read more